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Ltd. This is an open access article undAbstract Background: Neurological disorders represent a profound healthcare problem ac-
counting for 6.3% of the global disease burden. Alzheimer’s disease alone is expected to impact
over 115 million people worldwide by 2050 with a cost of over $1 trillion per year to the U.S.
economy. Despite considerable advances in our understanding of the pathogenesis and natural
history of neurological disorders, the development of disease modifying therapies have failed
to keep pace. This lack of effective treatments is directly attributable to the presence of the
bloodebrain and bloodecerebrospinal fluid barriers (BBB and BCSFB) which prevent up to 98%
of all potential neuropharmaceutical agents from reaching the central nervous system (CNS).
These obstacles have thereby severely limited research and development into novel therapeu-
tic strategies for neurological disease. Current experimental methods to bypass the BBB,
including pharmacologic modification and direct transcranial catheter implantation, are
expensive, are associated with significant complications, and cannot be feasibly scaled up
to meet the chronic needs of a large, aging patient population.
Transmucosal drug delivery: An innovative method of direct CNS drug delivery using hetero-
topic mucosal grafts was described. This method is based on established endoscopic skull base
nasoseptal flap reconstruction techniques. The model has successfully demonstrated CNS de-
livery of chromophore-tagged molecules 1000 times larger than those typically permitted by
the BBB.of Otology and Laryngology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston,
oo.com.br (M.M. Miyake).
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12 M.M. Miyake, B.S. BleierConclusions: This innovative technique represents the first described method of permanently
bypassing the bloodebrain barrier using purely autologous tissues. This has the potential to
dramatically improve the current treatment of neurological disease by providing a safe and
chronic transnasaldelivery pathway for high molecular weight neuropharmaceuticals.
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behalf of KeAi Communications Co., Ltd. This is an open access article under the CC BY-NC-
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The spectrum of neurological disorders represents a pro-
found healthcare problem accounting for up to 6.3% of the
global disease burden according to the World Health Or-
ganization.1 By the year 2050, Alzheimer’s disease (AD)
alone is expected to afflict 115.4 million people with a cost
of $1.1 trillion to the US healthcare system.2 Similarly, the
US National Institute for Neurological Disorders and Stroke
estimated the total number of cases of Parkinson’s disease
(PD) in the US at 500,000 with 50,000 new cases diagnosed
annually resulting in a cost to the US economy of $23 billion
per year.3,4 While precise numbers are difficult to obtain,
the prevalence of PD in industrialized countries is esti-
mated at 1% for people over 60.5 The scale of this chronic
disease burden suggests that therapies capable of delaying
or reversing these disorders will translate into enormous
cost savings to the global healthcare system. Although re-
searchers have made considerable advances in our under-
standing of the pathogenesis and natural history of
neurological disease, the development of effective thera-
peutic options have failed to keep pace. For example
levodopa remains the most effective agent available for the
symptomatic treatment of PD despite the fact that it was
first introduced in 1961.6 The current paucity of effective
treatments for neurological disease is directly attributable
to the presence of the bloodebrain barrier (BBB) which
effectively prevents up to 98% of all potential neuro-
pharmaceutical agents from reaching the central nervous
system (CNS) thereby severely limiting the development
and implementation of novel disease modifying therapies.7Bloodebrain and bloodecerebrospinal fluid
barrier physiology
The BBB represents a dynamic interface between the CNS
and the periphery, which functions to protect the brain from
xenobiotic agents and toxins while selectively permitting
molecules essential formaintainingmetabolic homeostasis.7
The BBB is classically described within the microvascular
endothelial cells of the cerebrovasculature. However an
additional component, known as the bloodecerebrospinal
fluid barrier (BCSFB), is also present within the arachnoid
membrane surrounding the brain and spinal cord. The BCSFB
has been recognized since 1913 when Edwin Goldman
demonstrated that trypanblue failed todiffuse into theextra
axial tissues following injection into the cerebrospinal fluid
within the subarachnoid space.8,9 As theBBBandBCSFB share
similar morphologic and functional characteristics, theterms will be used interchangeably throughout this manu-
script. The BBB utilizes several mechanisms to restrict drug
delivery to the CNS. The first is a physical barrier comprised
of a thick basement membrane and densely packed cells
bonded through tight junctionswhich represent a complex of
transmembrane (junctional adhesion molecule-1, occludin,
and claudins) and cytoplasmic (zonula occludens-1 and -2,
cingulin, AF-6, and 7H6) proteins linked to the actin cyto-
skeleton.10 The BBB also functions as an enzymatic barrier by
degrading pharmaceuticals using a host of enzymes including
monoamine oxidase types A and B, L-amino acid decarbox-
ylase, several cytochrome P450 dependent mono-
oxygenases, NADPH-cytochrome P450 reductases, UDP-
glucuronosyltransferases, alkaline phosphatases, gluta-
thione peroxidases, and epoxide hydrolases.11 Finally, the
BBB employs a host of specific transportmechanisms, such as
the glucose transporter-1, which simultaneously enable the
uptake of large molecules and peptides necessary for CNS
function while actively excluding most exogenous drugs.7
The combination of these three barrier mechanisms re-
stricts simple diffusion only to small lipophilic drugs that
have a cross sectional area of less than 70 A˚2,9 or a molecular
weight of less than 500 Daltons (Da).11Current obstacles in neuropharmaceutical
delivery
The restrictions on drug uptake imposed by the BBB have
dramatically limited clinical progress in both symptomatic
and disease modifying therapies for neurological diseases.
Promising experimental therapies such as glucocere-
brosidase (60 kDa),12 IL13-Pseudomonas Toxin (66 kDa),13
IDUAe1 (73 kDa),14 CTP-MPB (85 kDa),15 and b-Galactosi-
dase (116 kDa)16 have been developed to treat several
devastating neurological disorders such as Gaucher’s Dis-
ease, Diffuse Pontine Glioma, Mucopolysaccharidosis I,
Alzheimer’s disease, and lysosomal storage disorders,
respectively. However, as these compounds exceed 500 Da,
their molecular weight precludes meaningful uptake by the
CNS. Glial derived neurotrophic factor (GDNF, 35 kDa)
represents the most intensely studied of these high mo-
lecular weight neuropharmaceuticals as it has been shown
to promote mesencephalic dopaminergic neuronal survival
thereby delaying or even reversing disease progression in
Parkinson’s Disease.17 The progressive global burden of
neurological disease coupled with the obstacles posed by
the presence of the BBB have catalyzed an enormous body
of research targeted at bypassing the bloodebrain barrier.
Current strategies can be broadly categorized into non-
Bypassing the bloodebrian barrier 13invasive and invasive methods, each of which is associated
with certain limitations. Non-invasive methods include
strategies such as 1) local permeabilization of the BBB via
osmotic18 or ultrasound disruption19 techniques, 2) phar-
macological approaches using fatty acid20 and lipid car-
riers,21 and 3)physiological approaches that exploit pre-
existing receptor mediated transport mechanisms such as
the transferrin16 and insulin22 uptake pathways. While
these methods have demonstrated promise in limited
studies, they are short lived, require extensive drug
manipulation, and would be extremely expensive to scale
up to meet the chronic needs of the growing population of
patients with neurological disease. Invasive methods rely
on physically breaching the BBB using intra-
cerebroventricular (ICV) infusion,23 convection enhanced
delivery,24 or simple direct intracerebral injection.25 As
noninvasive methods obviate the need for extensive drug
reformulation with its attendant regulatory considerations
and costs, these methods have been more extensively
tested in clinical trials. Gill et al26 reported on their
experience on direct intraputamenal GDNF injection in a
phase 1 safety trial in Parkinson’s disease. Though clinically
effective, all patients developed vasogenic edema at the
catheter tip and 40% required additional catheter manipu-
lation or explantation. These safety issues are emblematic
of the inherent complications associated with inducing
direct trauma to the brain for the purposes of drug delivery
as well as the implantation of catheters which are prone to
infection and malposition. These findings underscore the
fact that there remains a profound unmet need for a safe
method of chronically bypassing the bloodebrain barrier
without requiring direct intracerebral injections or the
placement of indwelling foreign bodies.
Potential of Direct Transnasal Drug Delivery: The evident
potential of high molecular weight neuropharmaceutical
delivery to the brain has driven considerable investigation
into the direct transnasal pathway. This method postulates
the retrograde axonal transport of drugs by neurons within
the olfactory mucosa and offers the additional advantage of
direct uptake into the CNS while avoiding the side effects
associated with systemic drug exposure.27 Using a modified
“Hirai” model, Fisher et al28 confirmed that transmucosal
absorption of molecules 70 kDa and larger is possible.
DeRosa et al29 reported that intranasal nerve growth factor
delivery (27.5 kDa) was capable of reversing cognitive de-
fects in AD mice through olfactory mucosa uptake. In a
clinical study, Reger et al30 exploited the presence of the
native BBB insulin receptor demonstrating that intranasal
insulin (5.8 kDa) was capable of improving cognition in AD
mice without altering plasma insulin levels. Of note, the
authors conceded that the insulin levels measured in the
CSF were up to 10 times lower than physiologic concen-
trations thereby calling into question the concentration of
insulin delivered and the mechanism underlying their clin-
ical endpoint. While these studies appear to support the
potential of simple transnasal drug delivery to the CNS, it
has been suggested that this pathway may not be sufficient
to provide a reliable platform for the delivery of a broad
range of neuropharmaceutical agents for three principle
reasons. First, the majority of preclinical studies demon-
strating the efficacy of this pathway rely on retrograde
uptake into the CSF through the olfactory mucosa in arodent model.31e33 While the olfactory epithelium occupies
up to 50% of the nose in a rodent, it comprises only 3% of
human nasal mucosa with a total surface area of
1e2 cm.2e4 This small region of olfactory tissue is then even
further reduced by progressive replacement with respira-
tory mucosa as human age thereby accounting for the
normal decline in smell function throughout life.34 This
implies that studies in rodents vastly overestimate the
surface area available for drug uptake clinically, particu-
larly when applied in an elderly population. Second, human
olfactory mucosa is located in a narrow recess in the roof of
the nasal cavity known as the olfactory cleft. As a result of
this unfavorable location, drug deposition in this region is
minimal regardless of the delivery method used.35 Third,
once the drug contacts the nasal epithelium it has an
effective mucosal residence time of only 15e20 min before
it is rapidly cleared out of the nose by mucociliary action.
This, coupled with the poor distribution to the olfactory
cleft, even further reduces the amount of agent available
for mucosal absorption.36 These factors serve to explain
why even when applying a relatively low molecular weight
molecule in the presence of a selective receptor mediated
insulin uptake pathway, the amount of insulin capable of
reaching the CNS in the Reger et al30 study still fell below
physiologic concentrations. These limitations effectively
rule out this pathway for other drugs requiring higher
therapeutic concentrations and lacking a similar native
uptake mechanism. Merkus et al37 summarized these con-
cerns regarding the clinical utility of transnasal drug de-
livery noting that among 100 preclinical and clinical papers
studying this pathway, only 2 provided convincing evidence
of direct CNS uptake, both of which were in rat models.
While this evidence demonstrates the limitations of the
clinical potential for direct transnasal CNS neuro-
pharmaceutical delivery, the considerable permeability
demonstrated by the sinonasal mucosa to high molecular
weight agents does suggest the feasibility of alternative
transmucosal pathways.Endoscopic skull base reconstruction
Endoscopic access to lesions that involve the brain paren-
chyma requires the removal of the intervening tissues
including nasal mucosa, bone, dura, and arachnoid mem-
brane to facilitate complete resection. These approaches
thereby necessitate creating a large window in the skull
base which allows for direct communication between the
CSF space, brain, and the interior of the nasal cavity.
Consequently, the ability to safely and reliably reconstruct
these defects is an absolute requirement in the successful
performance these surgeries.38 Over the past decade, a
variety of mucosal grafts39e42 have been developed for the
specific purpose of skull base reconstruction, providing for
reliable, water-tight, and immunocompetent repairs which
safely and permanently separate the intranasal and intra-
cranial compartments for defects up to 20 cm.2,43,44 These
repairs are extraordinarily safe with rates of long term
infection, CSF leak, and mucocele formation estimated at
approximately <1%, 5%,45 and 3.6%,43 respectively. The
proven long term safety profile of mucosal graft recon-
struction of large skull base defects has catalyzed a
14 M.M. Miyake, B.S. Bleierdramatic expansion in the use of these techniques with
endoscopic surgeons currently performing this procedure
routinely throughout the world. As nasal mucosa is known
to be over 1000 times more permeable than the native
BBB,46 an unanticipated side effect of this technique is the
creation of a semipermeable conduit for high molecular
weight drug delivery directly to the CSF and brain.Transmucosal drug delivery using mucosal graft
techniques
In order to explore this potential, our team embarked on a
research program to develop a mouse model of mucosal
graft reconstruction in order to test the feasibility of using
nasal mucosal grafts for high molecular weight drug de-
livery to the brain.46 This model recapitulated the anatomy
and graft morphology encountered at the anterior skull
base. Briefly, the nasal septum was harvested en bloc from
a donor mouse and was used to repair a craniotomy defect
following arachnoid resection.
In our findings we demonstrated that the mucosal graft is
capable of transporting molecules 1000 larger than those
excluded by the BBB directly into the brain. When exam-
ining dextran conjugated fluorophores ranging from 20 to
500 kDa, we found that transmucosal uptake and spatial
distribution were directly correlated with duration of
exposure and inversely correlated with molecular weight.
The detailed results of these findings have been previously
reported.46Discussion
The BBB continues to be the greatest obstacle to the
elaboration and implementation of effective pharmaceu-
tical therapies for a variety of neurologic disorders. The
development of a safe and reliable method to bypass the
BBB represents a “holy grail” of neuropharmacology. Our
data demonstrate that the application of nasal mucosal
grafts over arachnoid defects may represent one such
method by creating a permanent semipermeable conduit
directly from the nose to the CNS. Utilization of nasal
mucosal grafting offers several advantages over previously
described methods: 1) Compared to ICV catheter place-
ment, the mucosal graft allows for drug diffusion directly
into the CSF within the subarachnoid space adjacent to the
basolateral side of the graft. As the CSF continually circu-
lates with a turnover rate of 10e20 mL per hour,47 a
counter-current exchange phenomenon occurs continually
maximizing the diffusion gradient across the graft. How-
ever, the graft utilizes only autologous tissues and avoids
penetration of the brain parenchyma thereby obviating the
complications, such as vasogenic edema and catheter
malposition, seen with traditional ICV studies.26 Further-
more the long track record of safety associated with
endoscopic skull base repairs43,45 ensures that the graft
remains stable over the lifetime of the patient without
incurring significant risk of infection, CSF leak, or ascending
meningitis. 2) Unlike non-invasive pharmacologic20,21 and
physiologic16,22 methods of BBB disruption, the mucosal
graft is inherently permeable to a broad range of highmolecular weight compounds enabling the delivery of both
experimental and currently available agents without the
need for expensive drug manipulation. 3) Pharmaceutical
distribution and mucosal residence time at the surface of
the graft is dramatically enhanced relative to simple
transnasal olfactory epithelium delivery. This results from
the position of the graft within the sphenoid which creates
a natural reservoir to retain a higher volume of the drug
despite the clearance action associated with mucociliary
transport.36 Furthermore, the graft provides 10e20 times
the surface area of healthy olfactory epithelium and does
not diminish with age.44
Conclusion
Drug permeability across the BBB is highly limited and none
delivery technique have proved to be sufficiently effective
in reaching the brain. The heterotopic mucosal grafting
technique represents a completely novel method of
permanently bypassing the BBB using purely autologous
tissues. This approach has the potential to dramatically
improve the current treatment of neurological disease by
enabling the delivery of high molecular weight neuro-
pharmaceuticals directly to the CNS.
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